Clinical Trial Challenges: FDA Wants More Prospective Studies, Validated Biomarkers
Executive Summary
NIH Director Collins and FDA Commissioner Califf discuss difficulties with ‘big science,’ ‘small crappy trials,’ and ‘data landlords.’
You may also be interested in...
ClinicalTrials.gov Still Lacks Many Study Results, JAMA Finds; Do Transparency Efforts Need A Boost?
Industry data transparency initiatives are well-established now, but JAMA study suggests holes in efforts to publicly release clinical trial results.
Gottlieb: If Trials Show 'More Certain Benefit,' Risk Can Be Considered Long-Term
US FDA Commissioner says that with strong benefit shown, some risks can be discharged postmarket.
NIH/Industry Oncology Partnership Aims For Immunotherapy Biomarkers
The US National Institutes of Health will team up with 11 different drug-makers to explore new biomarkers with a vision of precision oncology medicine.